New combo therapy aims to boost immune response in hard-to-treat lung cancer bone metastases

NCT ID NCT06738160

First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This study tests whether adding a drug called narlumosbart and precise radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the bones. The drug and radiation are meant to improve the immune system's ability to fight the cancer. About 27 adults with this type of cancer will receive the combination treatment, and researchers will measure how many patients' tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.